We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vertex Bags Experimental Drug for Rare Liver Disease after Disappointing Phase 2 Results
Vertex Bags Experimental Drug for Rare Liver Disease after Disappointing Phase 2 Results
Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial.